Trial Profile
Safety and antiviral activity of ABT-267, a novel NS5A inhibitor, during 3-day monotherapy: first study in HCV genotype-1 (GT1)-infected treatment-naïve subjects
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 May 2012
Price :
$35
*
At a glance
- Drugs Ombitasvir (Primary)
- Indications Hepatitis C
- Focus Adverse reactions
- 10 May 2012 New trial record
- 22 Apr 2012 Results presented at the 47th Annual Meeting of the European Association for the Study of the Liver.